Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA approves Abbott's LCx gonorrhoea test:

This article was originally published in Clinica

Executive Summary

Abbott Laboratories has received US FDA approval for its gonorrhoea test for use with the company's LCx Probe System. The new test, based on Abbott's ligase chain reaction amplification technology, will allow laboratories to detect gonorrhoea in urine samples, as well as with swabs. It can be used in tandem with the company's LCx chlamydia test. Current tests for gonorrhoea, which is often asymptomatic and underdiagnosed, are "invasive, uncomfortable, time-consuming and labour-intensive", says Abbott. As a result they are not commonly used unless patients believe they have been infected.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT088175

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel